Loading…
Hong Kong-listed Chinese drugmaker: nuclear-medicine cancer therapies, critical-care and respiratory drugs, ophthalmology and heart-brain emergency medicines.
Hong Kong-listed Chinese drugmaker: nuclear-medicine cancer therapies, critical-care and respiratory drugs, ophthalmology and heart-brain emergency medicines.
Sells prescription drugs for emergency, critical-care, respiratory and eye conditions to hospitals, where older products face government bulk-purchase price cuts. Its growth push is nuclear medicine, radioactive cancer treatments, led by yttrium-90 microspheres already on sale, with in-house radioligand drugs in trials.
Moat: narrow (IP / patents, regulatory licence). Licensed specialty drugs and a scarce nuclear-medicine franchise; older products face procurement pricing pressure.
Headquarters: Wuhan, China · Employees: 12,614
Size Grand Pharmaceutical (0512.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.01B, the 419th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$4.45 on 6 Nov 2026.
Performance Over six months the shares fell 27.2%, against +5.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 7.3% over the last twelve months (peer median +6.5%); the operating margin is 13.3% (peer median 15.4%).
Valuation It trades at 9.8× forward earnings against a peer median of 23.3× (3rd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.9 points below its cost of capital (7.4% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$12.6B | HK$12.3B | HK$11.6B | HK$10.5B | HK$9.56B |
| Revenue growth | — | +5% | +11% | +10% | — |
| Gross profit | HK$6.55B | HK$6.78B | HK$6.74B | HK$6.52B | HK$5.95B |
| EBITDA | HK$2.32B | HK$2.13B | HK$2.55B | HK$3.06B | HK$2.91B |
| Net income | HK$1.13B | HK$1.24B | HK$2.47B | HK$1.88B | HK$2.08B |
| Free cash flow | HK$838M | HK$774M | HK$1.14B | HK$1.73B | HK$1.26B |
| Capital expenditure | HK$1.50B | HK$1.52B | HK$678M | HK$498M | HK$1.67B |
| Total debt | n/a | HK$4.72B | HK$4.44B | HK$3.40B | HK$4.48B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Grand Pharmaceutical 0512.HK | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% |
| China Medical System 0867.HK | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% |
| Hansoh Pharma 3692.HK | $26.9B | -7% | +25% | 38% | 27.5× | 8.9% |
| Boston Scientific BSX | $62.0B | -21% | +9% | 21% | 13.8× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0512.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.8% | -1.2% | 9th lowest of 21 |
| 6-month return | -27.2% | +5.3% | 3rd lowest of 21 |
| Distance from 52-week high | -49.9% | -25.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | +7.3% | +6.5% | 11th highest of 21 |
| Operating margin | 13.3% | 15.4% | 10th lowest of 21 |
| Forward P/E | 9.8× | 23.3× | 3rd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 1.2% | 9.1% | 7th least demanding of 18 |
| Growth delivered (Del g) | +14.1% | +8.0% | 5th highest of 18 |
| Hurdle (Req g minus delivered) | -12.8 pp | -0.2 pp | 5th least demanding of 18 |
| ROIC minus cost of capital | -0.9 pp | +0.4 pp | 9th lowest of 21 |
| EV / EBITDA | 8.5× | 14.3× | 4th cheapest of 10 |
| Net debt / EBITDA | 1.6× | 0.9× | 4th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |